FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Paxil | Supreme Court | preemption

Judge reverses Paxil preemption ruling

Tools

Pre-emption fans took one on the chin last week when a federal judge changed his mind. U.S. District Court Judge David Hamilton reversed a previous opinion that dismissed a Paxil suicide case, saying that FDA approval would shield drugmakers from state-court claims. In his new opinion, Hamilton wrote that he had "failed to appreciate the significance of the fact that the ongoing ability, authority, and responsibility to strengthen a label still rests squarely with the drug manufacturer."

That Paxil case--brought by a woman whose brother, a priest, shot himself 22 days after starting the drug--will be reopened. But like so many other state-court claims brought by patients, it could be rendered moot this fall when the Supreme Court hears a case widely considered to be an opportunity for the justices to confirm pre-emption.

 - see the post at Pharmalot

Related Articles:
Reps introduce anti-preemption bill
Quaid: Preemption unfair to patients
Preemption debate heats up
Supremes vote 4-4 in pre-emption suit

More stories about Paxil   Supreme Court   preemption  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 19 + 28?
To combat spam, please solve the math question above.